Are we prepared to deliver gene‐targeted therapies for rare diseases?
American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2023-03 · 193 (1) · 7-12
DOI: 10.1002/ajmg.c.32029 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 24.01.2023. Verfasst von Timothy W Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Genomics, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Rare Diseases, Genetic Therapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
The cost and time needed to conduct whole‐genome sequencing (WGS) have decreased significantly in the last 20 years. At the same time, the number of conditions with a known molecular basis has steadily increased, as has the number of investigational new drug applications for novel gene‐based therapeutics. The prospect of precision gene‐targeted therapy for all seems in reach… or is it? Here we consider practical and strategic considerations that need to be addressed to establish a foundation for the early, effective, and equitable delivery of these treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Genetics and Genomics, Harvard Medical School, Boston, Massachusetts, USA.
- Rady Children's Institute for Genomic Medicine, San Diego, California, USA.
- Department of Genetics-Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Surgery and the Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, San Francisco, California, USA.
- Division of Pediatric Genetic Medicine, Children's Hospital at Montefiore, New York, New York, USA.
- Division of Genetics, New York State Department of Health, Albany, New York, USA.
ORCID-Profile: Stephen F Kingsmore, Robert C Green, Jill A Morris, Melissa A Parisi, Tiina K Urv
Förderung
- National Center for Advancing Translational Sciences
Zitieren
APA
Yu, T. W., Kingsmore, S. F., Green, R. C., MacKenzie, T., Wasserstein, M., Caggana, M., Gold, N. B., Kennedy, A., Kishnani, P. S., Might, M., Brooks, P. J., Morris, J. A., Parisi, M. A., & Urv, T. K. (2023). Are we prepared to deliver gene‐targeted therapies for rare diseases?. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 193(1), 7-12. https://doi.org/10.1002/ajmg.c.32029
Vancouver
Yu TW, Kingsmore SF, Green RC, MacKenzie T, Wasserstein M, Caggana M, et al. Are we prepared to deliver gene‐targeted therapies for rare diseases?. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2023;193(1):7-12. doi:10.1002/ajmg.c.32029
BibTeX
@article{Yu2023,
author = {Yu, Timothy W and Kingsmore, Stephen F and Green, Robert C and MacKenzie, Tippi and Wasserstein, Melissa and Caggana, Michele and Gold, Nina B and Kennedy, Annie and Kishnani, Priya S and Might, Matthew and Brooks, Phillip J and Morris, Jill A and Parisi, Melissa A and Urv, Tiina K},
title = {Are we prepared to deliver gene‐targeted therapies for rare diseases?},
journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
year = {2023},
volume = {193},
number = {1},
pages = {7--12},
doi = {10.1002/ajmg.c.32029}
}
EUVIMED